NCT06849492

HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer

An Open, Multicenter Study on the Treatment of Recurrent and Metastatic Triple-negative Breast Cancer Guided by Cell Surface Protein Typing (HIM) in Triple-negative Breast Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To explore the efficacy and safety of treatment for recurrent and metastatic advanced first-line triple-negative breast cancer guided by cell surface protein-based subtyping (HIM).

Conditions

• Advanced Triple Negative Breast Cancer

Interventions

Type	Name	Description
DRUG	Camrelizumab	PD-1 inhibitor
DRUG	Nab-paclitaxel	chemotherapy
DRUG	SKB264	Trop2-ADC
DRUG	Lenvatinib	Anti-angiogenic TKI

Timeline

• Start date: 2025-04-01
• Primary completion: 2027-12-31
• Completion: 2028-12-31
• First posted: 2025-02-27
• Last updated: 2025-02-27

Locations

1 site across 1 country: China